PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: General Electric Company

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

DATSCAN™ (IOFLUPANE I 123 injection) Recommended in Updated European Guidelines for Diagnosis of Alzheimer's Disease - European Federation of the Neurological Societies Cites Utility of DaTSCAN in Differentiating Alzheimer’s Disease from Dementia with Lewy Bodies
DATSCAN™ (IOFLUPANE I 123 injection) Recommended in Updated European Guidelines for Diagnosis of Alzheimer's Disease


NewswireToday - /newswire/ - Princeton, NJ, United States, 2010/10/15 - European Federation of the Neurological Societies Cites Utility of DaTSCAN in Differentiating Alzheimer’s Disease from Dementia with Lewy Bodies. NYSE: GE

Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


GE Healthcare, a unit of General Electric Company (NYSE:GE), today announced that DaTSCAN™ (ioflupane I 123 injection), a radiopharmaceutical agent intended for use with single photon emission computed tomography (SPECT) imaging of the brain, has been recommended in updated European Federation of the Neurological Societies (EFNS) guidelines for the diagnosis and management of Alzheimer’s disease (AD). The guidelines appear in the October issue of the European Journal of Neurology.[i]

Specifically, the guidelines, which were last issued in 2007[ii], note that SPECT “may increase diagnostic confidence in the evaluation of dementia,” adding that dopaminergic SPECT imaging with DaTSCAN is useful in differentiating AD from dementia with Lewy bodies (DLB)1, a neurological condition that is similar to AD in that it results from the death of nerve cells in the brain.[iii] The EFNS recommendation carries a level A grade of evidence – the strongest grade assigned in the guidelines – noting that DaTSCAN can differentiate AD from DLB with sensitivity and specificity of “around 85%.”1,2

“As the global population ages and the prevalence of dementia rises, it will become increasingly important to be able to differentiate Alzheimer’s disease from other types of dementia,” said Adrian Holden, EU Head of Medical Professional Services for GE Healthcare. “Neurologists will therefore become increasingly reliant on imaging technologies that can accurately yield a definitive diagnosis. We are pleased that the EFNS has recognized the value of DaTSCAN in facilitating diagnosis of dementia, particularly with regard to distinguishing Alzheimer’s disease from dementia with Lewy bodies. We hope the EFNS recommendation results in enhanced provision of timely and appropriate treatment to patients living with dementia – not only in Europe, but worldwide.”

Dementia is a general term for a group of symptoms – such as loss of memory, impaired judgment, language difficulty, loss of complex motor skills, and other cognitive dysfunction – resulting from permanent damage or death of the brain’s nerve cells.[iv] An estimated 24 million people around the world – including 5.4% of those aged 65 or older – are living with dementia; this figure is expected to double every 20 years to 42 million by 2020 and to 81 million by 2040. Of those living with dementia, 60% live in developing countries; this percentage is expected to rise to 71% by 2040.[v]

AD is the most common cause of dementia, representing about 60% of all dementias.4 An estimated 8.45 million people in Europe and 5.1 million people in the United States are thought to be living with AD.[vi],[vii] DLB, which is estimated to account for 10-20% of dementias[viii], takes its name from the abnormal collections of protein, known as Lewy bodies, in the nerve cells of the brain.3

“By specifically mentioning the utility of dopaminergic SPECT brain scanning (DaTSCAN) in differentiating Alzheimer’s disease from dementia with Lewy bodies in their new guidelines, the EFNS Scientist Panel on Dementia has underscored the importance of functional (SPECT) neuroimaging in the diagnostic work-up of patients with dementia,” commented John O’Brien, one of the authors of the guidelines and Professor of Old Age Psychiatry at the Institute for Ageing and Health at Newcastle University in Newcastle upon Tyne, U.K. “A timely and accurate diagnosis of dementia provides certainty for patients and their carers, can reduce their anxiety and allows them to better plan for the future and understand the symptoms they are experiencing. Early diagnosis is important as it can improve utilization of healthcare resources and contribute to improved long-term patient outcomes, while also potentially reducing the use of inappropriate medications that can sometimes have serious side effects.”

DaTSCAN was granted a Marketing Authorization by the European Commission in July 2000 for use in detecting loss of functional dopaminergic neurons (nerve cells in the brain) in patients with clinically uncertain Parkinsonian syndrome (PS). In July 2006, the European indication was expanded to include differentiation of probable DLB from AD. DaTSCAN is currently licensed and distributed in 32 countries, and has been in clinical use for ten years in more than 300,000 patients worldwide.[ix],[x]

In March 2009, GE Healthcare submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DaTSCAN for striatal dopamine transport (DaT) visualization in the brain of adult patients with suspected PS. Dopamine is a brain chemical that is classified as a neurotransmitter and is found in regions of the brain that regulate movement, emotion, motivation, and pleasure. Due to an unmet clinical need for an imaging agent to assist physicians in managing patients according to their dopaminergic status, GE Healthcare was granted “Priority Review” of the DaTSCAN NDA.9

About GE Healthcare

GE Healthcare ( provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems. Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries.

[i] Hort J, O’Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol 2010;17(10):1229-1235.

[ii] Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:e1-e26.

[iii] Dementia with Lewy bodies. Alzheimer’s Disease International Website at Updated November 20, 2007. Accessed September 30, 2010.

[iv] About dementia. Alzheimer’s Foundation of America Website at Accessed September 30, 2010.

[v] Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-2117.

[vi] Packo I. Dementia in Europe Yearbook 2008. Luxembourg: Alzheimer Europe, 2008.

[vii] About Alzheimer’s – statistics. Alzheimer’s Foundation of America website at Accessed September 30, 2010.

[viii] Dementia with Lewy bodies. MedScape eMedicine Neurology Website at Updated December 23, 2009. Accessed August 30, 2010.

[ix] Transcript from Peripheral and Central Nervous System Advisory Committee Meeting, August 11, 2009. Rockville, MD: U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2009. Accessed October 12, 2010.

[x] Data on file. GE Healthcare.

Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: General Electric Company


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!

DATSCAN™ (IOFLUPANE I 123 injection) Recommended in Updated European Guidelines for Diagnosis of Alzheimer's Disease

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

GE News Center |
Publisher Contact: Aleisia Gibson - GE Healthcare 
+1 (609) 514-6046 aleisia.gibson[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any General Electric Company securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From General Electric Company / Company Profile

Read Health/Surgery Most Recent Related Newswires:

Lutein & Zeaxanthin Supplementation Could Save EU Billions in Healthcare Costs Associated with Age-related Macular Degeneration Says Frost & Sullivan
Frost & Sullivan Commends Columbia Pacific’s Clear Vision in the Healthcare Delivery Space and Senior Living Services
Global Acute Myeloid Leukemia Treatment Market to Reach US$ 1.17 Billion by 2021 According to iHealthcareAnalyst, Inc.
Frost & Sullivan Recognizes Prognos for its Commitment to Develop Novel Artificial Intelligence Based Platfor
DSM Partners with the Musculoskeletal Transplant Foundation for Distribution of Regenerative Materials and Products
Sturge-Weber Foundation and Lurie Children’s Hospital Host Sturge-Weber Syndrome Education Forum
USACS Announces New Integrated Acute Care Partnership with Sharon Regional Health System
Frost & Sullivan Highlights STANLEY Healthcare's Design Innovation and Leadership in Addressing the Changing Needs of the Senior Living Industry
USACS Additional Integrated Acute Care Partnership with MetroSouth Medical Center
Big Data Analytics to Disrupt U.S. Next-generation Sequencing Informatics Market with Double-digit Growth
Bionic Prosthetics Manufacturers Drive R&D Initiatives across Emerging Markets to Impel its Adoption
Frost & Sullivan Acclaims CGI’s Advanced Genomic & Biomarker Technologies That Drive Industry Innovation in Support of Precision Cancer Treatment
Frost & Sullivan Honors Linguamatics for Developing a Best-in-Class NLP-based Data Mining Platform for the Healthcare Industry
Therapist Launches Podcast to Reach Larger Audience
Top Innovative Health and Wellness Technologies to Accelerate Global Adoption of Precision Medicine Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business




  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (